Purpose

This report seeks approval of a variation to
the contract for Camden’s Adult Substance Misuse Treatment
and Recovery Service. The contract was awarded in November 2022 to
Change Grow Live Services Ltd (CGL) and began on 1st April 2023.
The clauses within the contract permit for variations in Years 1-3
to reflect Supplementary Substance Misuse Treatment and Recovery
Grant allocations. These were added following discussions with
legal and procurement colleagues to ensure the contract was
sufficiently flexible and new investment could be mobilised
quickly. 
The grant is now known as the Drug
and Alcohol Treatment and Recovery Grant (DATRIG) and will be
referred to as such throughout the report.
 
On 18th
December 2024, Camden were
notified by the Office of Health Improvement and Disparities
(OHID), that their DATRIG allocation for 2025-26 would be
£2,792,326 (indicative amount).  Since then, officers have been liaising with
key delivery partners and grant leads at OHID to agree how the
grant can be spent to support Camden in achieving the outcomes
outlined in the national Drug Strategy. Out of the total grant
allocation officers are proposing to allocate a maximum of
£2,571,326 to CGL to deliver a number of funded
interventions. It is also proposed that the contract is varied to
increase the contract price for 2025/26 by a further £36,000
allocated from the Rough Sleeper Drug and Alcohol Treatment Grant
(RSDATG) to fund in-patient detox and residential rehabilitation
and for 2025/26 to 2028/29 by £212,000 (£53,000 per
annum) from the Public Health Drug and Alcohol Cost Centre to
continue providing a Drug Strategy/Drug Related Death Lead
role.
 
This report is being presented to the Director
of Health and Wellbeing and the Executive Director Corporate
Services in accordance with Contract Standing Orders E2 and
F3. 

Content

That the Director of Health and Wellbeing
approves the following variations of the contract with Change Grow
Live Services Ltd:
 

1.    
To increase the contract price for
2025/26 at a cost of £2,571,326 to reflect the agreed Drug
and Alcohol Treatment and Recovery Improvement Grant interventions
set out in Appendix 1. 

2.    
To increase the contract price for
2025/26 at a cost of £36,000 to reflect the agreed Rough
Sleeper Drug and Alcohol Treatment Grant interventions set out in
Appendix 1.

3.    
To increase the contract price for
2025/26 to 2028/29 at a cost of £212,000 in total
(£53,000 per annum) to reflect the continued provision of a
Drug Strategy and Drug Related Deaths/Harm role set out in Appendix
1.
 
That the Executive Director Corporate Services
approves the waivers to implement the variations further to
Recommendations 2 and 3.